Coadministration has not been studied. Atorvastatin is metabolised mainly by CYP3A4. Based on drug-drug interaction studies with other NNRTIs and considering that nevirapine is a weak CYP3A4 inducer, coadministration is predicted to minimally impact atorvastatin exposure. No a priori dosage adjustment of atorvastatin is needed due to coadministration with nevirapine. However, treatment with statins requires periodic monitoring of lipid values and the atorvastatin dose should be adjusted based on the clinical response.